{
  "source": "PA-Notification-Otezla.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1129-15\nProgram Prior Authorization/Notification\nMedication Otezla® (apremilast)\nP&T Approval Date 5/2014, 10/2014, 2/2015, 3/2016, 3/2017, 3/2018, 3/2019, 3/2020, 3/2021,\n2/2022, 2/2023, 7/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nOtezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of\nadult patients with active psoriatic arthritis, for the treatment of adult patients with plaque\npsoriasis who are candidates for phototherapy or systemic therapy, for the treatment of\npediatric patients 6 years of age and older and weighing at least 20 kg with moderate to\nsevere plaque psoriasis who are candidates for phototherapy or systemic therapy and for the\ntreatment of adult patients with oral ulcers associated with Behçet’s disease.1\n2. Coverage Criteriaa:\nA. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Otezla will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Otezla in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Cosentyx (secukinumab), Enbrel (etanercept), Orencia\n(abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi\n(risankizumab), Taltz (ixekizumab), Tremfya (guselkumab), Xeljanz/Xeljanz\nXR (tofacitinib), ustekinumab]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Otezla will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Otezla therapy\n-AND-\n(2) Patient is not receiving Otezla in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n© 2025 UnitedHealthcare Services, Inc.\n1\n(certolizumab), Cosentyx (secukinumab), Enbrel (etanercept), Orencia\n(abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi\n(risankizumab), Taltz (ixekizumab), Tre",
    "ealthcare Services, Inc.\n1\n(certolizumab), Cosentyx (secukinumab), Enbrel (etanercept), Orencia\n(abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi\n(risankizumab), Taltz (ixekizumab), Tremfya (guselkumab), Xeljanz/Xeljanz\nXR (tofacitinib), ustekinumab]\nAuthorization will be issued for 12 months.\nB. Plaque Psoriasis\n1. Initial Authorization\na. Otezla will be approved based on both of the following criteria:\n(1) Diagnosis of plaque psoriasis who are candidates for phototherapy or systemic\ntherapy.\n-AND-\n(2) Patient is not receiving Otezla in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Cosentyx (secukinumab), Enbrel (etanercept), Ilumya\n(tildrakizumab), Skyrizi (risankizumab), Siliq (brodalumab), Sotyktu\n(deucravacitinib), Taltz (ixekizumab), Tremfya (guselkumab), ustekinumab]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Otezla will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Otezla therapy\n-AND-\n(2) Patient is not receiving Otezla in combination with another targeted\nimmunomodulator [e.g., adalimumab, Bimzelx (bimekizumab-bkzx), Cimzia\n(certolizumab), Cosentyx (secukinumab), Enbrel (etanercept), Ilumya\n(tildrakizumab), Skyrizi (risankizumab), Siliq (brodalumab), Sotyktu\n(deucravacitinib), Taltz (ixekizumab), Tremfya (guselkumab), ustekinumab]\nAuthorization will be issued for 12 months.\nC. Behçet’s disease\n1. Initial Authorization\na. Otezla will be approved based on all of the following criteria:\n(1) Diagnosis of Behçet’s disease\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(2) Patient has oral ulcers attributed to Behçet’s disease\n-AND-\n(3) Patient is not receiving Otezla in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Simponi (golimumab),\ntocilizumab]\nAuthorization will be issued for 12 ",
    "geted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Simponi (golimumab),\ntocilizumab]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Otezla will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Otezla therapy\n-AND-\n(2) Patient is not receiving Otezla in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Simponi (golimumab),\ntocilizumab]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.; April 2024.\nProgram Prior Authorization/Notification - Otezla (apremilast)\nChange Control\n5/2014 New program.\n10/2014 Added new indication for plaque psoriasis.\n2/2015 No change to coverage criteria. Minor reformatting. Updated clinical\nrules and background.\n© 2025 UnitedHealthcare Services, Inc.\n3\n3/2016 No change to coverage criteria. Updated reference.\n3/2017 Annual review with no changes to criteria.\n3/2018 Annual review with no changes to criteria. Updated reference.\n7/2018 Administrative change to include Oxford effective date.\n3/2019 Annual review with no change to coverage criteria.\n3/2020 Annual review. Updated background and criteria to include coverage\nfor new indication for oral ulcers associated with Beh",
    "fective date.\n3/2019 Annual review with no change to coverage criteria.\n3/2020 Annual review. Updated background and criteria to include coverage\nfor new indication for oral ulcers associated with Behçet’s disease.\n3/2021 Annual review with no change to clinical criteria. Updated\nreauthorization from 24 months to 12 months to align with other\nprograms. Reference updated.\n2/2022 Updated background and coverage criteria with expanded plaque\npsoriasis indication. Updated reference.\n2/2023 Annual review. Updated listed examples from Humira to adalimumab\nand added Rinvoq. Added state mandate footnote.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n6/2024 Updated background to reflect new indication for pediatrics with plaque\npsoriasis. Updated reference.\n6/2025 Annual review with no change to clinical criteria. Updated not used in\ncombination examples with no change to clinical intent.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}